Li Jianbiao, Zhu Ying-Hui, Huang Pinzhu, Zhang Baozhu, Sun Jian, Guan Xin-Yuan
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Block 2, Room 708, 651 Dongfeng East Road, Guangzhou, 510060, China.
Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Diagn Pathol. 2015 Aug 7;10:136. doi: 10.1186/s13000-015-0374-1.
Inositol-1,4,5-trisphosphate-3-kinase-A (ITPKA) has recently been found to be implicated in the tumor progression of various cancers. However, the expression and the prognostic value of ITPKA in hepatocellular carcinoma (HCC) remains unexplored. The aim of this study is to investigate the clinical significance of ITPKA expression in HCC.
We determined the expression level of ITPKA in 135 cases of HCC tissues and the matched adjacent nontumorous tissues by quantitative real-time RT-PCR. The correlation between ITPKA expression and prognosis of HCC patients was further evaluated by univariate and multivariate analysis. Multivariate analysis of the prognostic factors was performed with Cox proportional hazards model.
Up-regulation of ITPKA occurred in 48.9% of primary HCCs compared with their nontumor counterparts (P < 0.001). In addition, high expression of ITPKA was significantly associated with vascular invasion (P = 0.001) and TNM stage (P = 0.005). Kaplan-Meier analysis showed that the 5-year overall survival (OS) and relapse-free survival (RFS) rate in the group with high expression of ITPKA is poorer than that in low expression group (32.2 and 26.8% versus 59.2 and 57.7%). Univariate and multivariate analyses revealed that ITPKA was an independent prognostic factor for OS and RFS. Moreover, Stratified analysis revealed that its prognostic significance still existed within the subgroup of patients with early clinical stage (TNM stage I) or normal serum AFP level (≤25 μg/L).
Our data indicated that ITPKA expression was significantly up-regulated in HCC and could serve as a potential novel prognostic biomarker for HCC patients after surgery.
肌醇-1,4,5-三磷酸-3-激酶-A（ITPKA）最近被发现与多种癌症的肿瘤进展有关。然而，ITPKA在肝细胞癌（HCC）中的表达及预后价值仍未被探索。本研究旨在探讨ITPKA在HCC中的表达的临床意义。
我们通过定量实时RT-PCR测定了135例HCC组织及其匹配的癌旁非肿瘤组织中ITPKA的表达水平。通过单因素和多因素分析进一步评估ITPKA表达与HCC患者预后的相关性。采用Cox比例风险模型对预后因素进行多因素分析。
与非肿瘤对应组织相比，48.9%的原发性HCC中ITPKA上调（P<0.001）。此外，ITPKA的高表达与血管侵犯（P=0.001）和TNM分期（P=0.005）显著相关。Kaplan-Meier分析显示，ITPKA高表达组的5年总生存率（OS）和无复发生存率（RFS）低于低表达组（32.2%和26.8%对59.2%和57.7%）。单因素和多因素分析显示，ITPKA是OS和RFS的独立预后因素。此外，分层分析显示，其预后意义在临床早期（TNM分期I）或血清AFP水平正常（≤25μg/L）的患者亚组中仍然存在。
我们的数据表明，ITPKA在HCC中表达显著上调，可作为HCC患者术后潜在的新型预后生物标志物。
